Recent Publications

Anaplastic thyroid cancer (ATC) is the most aggressive type of thyroid cancer, and there is an urgent need to develop model systems so that new drugs can be tested. Despite our efforts to maximize the combined treatment approaches integrating surgery, radiation and chemotherapy, most patients... Continue reading
Ho et al. report findings from a phase 2 study of selumetinib, a MEK inhibitor, in patients with metastatic thyroid cancer in the February 14, 2013 issue of The New England Journal of Medicine. In this landmark study the authors demonstrate that treatment with selumetinib is sufficient, in some... Continue reading


International Thyroid Oncology Group
5166 Commercial Drive
Yorkville, New York 13495